Neoadjuvant versus adjuvant chemotherapy for resectable non-small cell lung cancer debate revisited
| Autor: | Chan Yeu Pu, Sai Yendamuri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Chemotherapy business.industry Adjuvant chemotherapy medicine.medical_treatment Micrometastasis 030204 cardiovascular system & hematology medicine.disease law.invention 03 medical and health sciences Editorial Commentary 0302 clinical medicine Planned Dose Randomized controlled trial law 030220 oncology & carcinogenesis Internal medicine Medicine Non small cell business Lung cancer Adjuvant |
| Popis: | The use of adjuvant platinum-based chemotherapy for surgically resectable non-small cell lung cancer (NSCLC) has been well established by several randomized trials and meta-analysis which demonstrated clear survival benefit over no chemotherapy (1-5). However, evidence is less robust regarding the benefit of neoadjuvant chemotherapy (NC). Goals of administering chemotherapy in the preoperative setting (neoadjuvant) include increasing operability by possibly reducing tumor size, improving the likelihood of receiving the maximal planned dose, and reducing the likelihood of micrometastasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|